Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel

被引：0
|
作者：
Ya-nan Man
Yan-fang Chen
机构：
[1] The Second Hospital of Tianjin Medical University,Department of Radiation Oncology
来源：
International Urology and Nephrology | 2019年 / 51卷
关键词：
SII; -dimer; Fibrinogen; CRPC; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2189 / 2199
页数：10
相关论文
共 50 条
  • [1] Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel
    Man, Ya-nan
    Chen, Yan-fang
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2019, 51 (12) : 2189 - 2199
  • [2] The prognostic role of systemic immune-inflammation index, SII, in Metastatic Castration-Resistant Prostate Cancer patients
    Uzun, Mehmet
    Gokcek, Savas
    Kaya, Erhan
    Semiz, Huseyin Salih
    DISCOVER ONCOLOGY, 2025, 16 (01)
  • [3] Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer
    Veccia, Antonello
    Caffo, Orazio
    De Giorgi, Ugo
    Di Lorenzo, Giuseppe
    Ortega, Cinzia
    Scognamiglio, Florinda
    Aieta, Michele
    Facchini, Gaetano
    Mansueto, Giovanni
    Mattioli, Rodolfo
    Procopio, Giuseppe
    Zagonel, Vittorina
    D'Angelo, Alessandro
    Spizzo, Gilbert
    Bortolus, Roberto
    Donini, Maddalena
    Lo Re, Giovanni
    Massari, Francesco
    Vicario, Giovanni
    Zucali, Paolo A.
    Alesini, Daniele
    Bonetti, Andrea
    Mucciarini, Claudia
    Nicodemo, Maurizio
    Berruti, Alfredo
    Fratino, Lucia
    Lodde, Michele
    Messina, Caterina
    Perin, Alessandra
    Santini, Daniele
    Sava, Teodoro
    Tucci, Marcello
    Basso, Umberto
    Maines, Francesca
    Burgio, Luca S.
    Galligioni, Enzo
    FUTURE ONCOLOGY, 2016, 12 (04) : 493 - 502
  • [4] Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel
    Buttigliero, Consuelo
    Pisano, Chiara
    Tucci, Marcello
    Vignani, Francesca
    Bertaglia, Valentina
    Iaconis, Davide
    Guglielmini, Pamela
    Numico, Gianmauro
    Scagliotti, Giorgio V.
    Di Maio, Massimo
    ACTA ONCOLOGICA, 2017, 56 (04) : 555 - 562
  • [5] Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients
    Fan, Liancheng
    Wang, Rui
    Chi, Chenfei
    Cai, Wen
    Zhang, Yong
    Qian, Hongyang
    Shao, Xiaoguang
    Wang, Yanqing
    Xu, Fan
    Pan, Jiahua
    Zhu, Yinjie
    Xun Shangguan
    Zhou, Lixin
    Dong, Baijun
    Xue, Wei
    PROSTATE, 2018, 78 (04): : 250 - 256
  • [6] Management of metastatic castration-resistant prostate cancer after first-line docetaxel
    Harrington, J. A.
    Jones, R. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (14) : 2133 - 2142
  • [7] Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients
    Caffo, Orazio
    Lo Re, Giovanni
    Sava, Teodoro
    Buti, Sebastiano
    Sacco, Cosimo
    Basso, Umberto
    Zustovich, Fable
    Lodde, Michele
    Perin, Alessandra
    Facchini, Gaetano
    Veccia, Antonello
    Maines, Francesca
    Barile, Carmen
    Fratino, Lucia
    Gernone, Angela
    De Vivo, Rocco
    Pappagallo, Giovanni L.
    Galligioni, Enzo
    FUTURE ONCOLOGY, 2015, 11 (06) : 965 - 973
  • [8] Re: Clinical Outcomes in Octogenarians Treated with Docetaxel as First-Line Chemotherapy for Castration-Resistant Prostate Cancer
    Griebling, Tomas L.
    JOURNAL OF UROLOGY, 2017, 197 (01): : 155 - 156
  • [9] Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel
    Buttigliero, Consuelo
    Tucci, Marcello
    Vignani, Francesca
    Di Stefano, Rosario F.
    Leone, Gianmarco
    Zichi, Clizia
    Pignataro, Daniele
    Lacidogna, Gaetano
    Guglielmini, Pamela
    Numico, Gianmauro
    Scagliotti, Giorgio, V
    Di Maio, Massimo
    CLINICAL GENITOURINARY CANCER, 2018, 16 (04) : 318 - 324
  • [10] EFFECTIVENESS OF DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER IN THE FIRST TREATMENT LINE
    Villa, J. C.
    Espinosa, J.
    Gomez, R.
    Sanchez, V
    Lopez, R.
    Galan, R.
    Pineda, M. D.
    Perez, M.
    VALUE IN HEALTH, 2015, 18 (07) : A816 - A817
12345